Skip to main content
Premium Trial:

Request an Annual Quote

Eclipse Bioinnovations Closes $14M Series A Financing Round

NEW YORK – Eclipse Bioinnovations, a startup commercializing RNA analysis technologies, said on Tuesday that it has closed a $14 million Series A financing round.

Alexandria Venture Investments and iGlobe led the oversubscribed round, joined by Photon Venture Alpha and Phoenix Venture Partners. Hallie Kuhn, VP of science and technology at Alexandria, will join the company's board.

"This financing will propel our continued leadership in the field by supporting the development of our robust and innovative pipeline of technologies," Eclipsebio Cofounder and CEO Peter Chu said in a statement. The company plans to use the funding to expand its product line.

"COVID-19 RNA vaccines have validated the enormous potential of RNA as a therapeutic modality. Given the central role of RNA in regulating biological processes and disease, we believe that the field is poised for significant growth," Chu said.

A University of California, San Diego spinout, Eclipsebio offers technologies revealing RNA interactions with RNA binding proteins, RNA modifications such as m6A, alternative transcription start site and polyadenylation site usage, and microRNA-mRNA interactions. The firm is working on technologies to profile translation to proteins and to probe RNA structure.

Eclipsebio has also received $1.1 million as part of a Small Business Innovation Research grant from the National Human Genome Research Institute.

The company offers its technologies as services and kits and provides custom RNA genomics services for select partners.